# Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

Source: https://onco.cc/trials/nct04550260/  
OnCo record `nct04550260` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab, Cisplatin and Capecitabine in oesophageal cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC is a phase 3 interventional study registered as NCT04550260 by AstraZeneca, with 640 participants enrolled, started 2020-10-19 and due to reach its primary completion in 2027-06-30. Interventions recorded: Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine and Radiation.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04550260
- Phase: 3
- Setting: A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)
- Sponsor: AstraZeneca
- Enrolled: 640

## Sources

- ClinicalTrials.gov NCT04550260: https://clinicaltrials.gov/study/NCT04550260

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04550260.json